Compare VanEck Video Gaming and eSports ETF (ESPO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Video Gaming and eSports ETF vs Viatris Inc — how do they compare? VanEck Video Gaming and eSports ETF trades at $97.96, while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while VanEck Video Gaming and eSports ETF pays none, and Viatris Inc is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| ESPO | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $122.30 | $17.86 |
52-Week Low | $85.25 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $97.97, down 1.64% today, with a bullish technical signal from moving averages and oscillators. Key support lies at $98, with resistance at $100. The stock shows strong momentum indicators, including a 6-day ADX of 55.42 signaling a strong trend. Recent financial data is unavailable, requiring updated SEC filings for fundamental assessment.
The outlook hinges on upcoming earnings to validate growth; risks include market volatility and lack of recent financial disclosures. Analyst sentiment is cautiously optimistic given technical strength, but fundamental clarity is needed for sustained upside.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
